Volume | 593,131 |
|
|||||
News | - | ||||||
Day High | 3.53 | Low High |
|||||
Day Low | 3.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.37 | 3.28 | 3.53 | 3.52 | 3.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,612 | 593,131 | $ 3.43 | $ 2,034,126 | - | 2.12 - 5.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:10 | 2 | $ 3.52 | USD |
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.81M | 40.09M | - | 0 | -56.8M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mind Medicine MindMed News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.75 | 3.53 | 2.75 | 3.12 | 445,572 | 0.7899 | 28.72% |
1 Month | 2.76 | 3.53 | 2.41 | 2.84 | 389,962 | 0.7799 | 28.26% |
3 Months | 3.99 | 4.51 | 2.41 | 3.16 | 374,126 | -0.4501 | -11.28% |
6 Months | 3.52 | 5.01 | 2.41 | 3.76 | 478,664 | 0.0199 | 0.57% |
1 Year | 2.56 | 5.01 | 2.12 | 3.50 | 494,118 | 0.9799 | 38.28% |
3 Years | 86.55 | 86.55 | 2.12 | 29.04 | 3,476,463 | -83.01 | -95.91% |
5 Years | 86.55 | 86.55 | 2.12 | 29.04 | 3,476,463 | -83.01 | -95.91% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |